Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2527-2545
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2527
Table 4 Clinical, laboratory, therapeutic and outcome data in 3 patients with systemic lupus erythematosus-autoimmune hepatitis overlap disease1
Patient number
1
2
3
SexFemaleFemaleFemale
SLE Dx age195020
ACR criteria8/117/118/11
AIH Dx age263722
IAIHG scoreDefiniteDefiniteDefinite
Clinical
SLESkin, joint, renal, hematology, neurologySkin, joint, renal, hematology, serositisSkin, joint, renal, hematology, serositis
AILD complicationJaundice, malaise LC with PHJaundice, pruritus hepatosplenomegalyJaundice, anorexia
Coexistent AIDNilPBC, SSNil
Laboratory
HemogramHA, TPHA, TP, leukopeniaTP, leukopenia
Proteinuria autoantibody2 g/d2.5 g/d1 g/d
SLE-relatedANA, anti-dsDNA/SmANA, anti-dsDNA/Sm ANA, anti-dsDNA
AILD-relatedASMA AMA, ASMAASMA
OthersARPA, ANCAARPA, anti-Ro/LaARPA
2IgG (mg/dL)213025201615
2AST (IU/L)156311697
2ALT (IU/L)1093217177
2Bil (mg/dL)23.83.72.4
2ALP (IU/L)432621344
HLA-DRDR8, DR15DR4, DR15DR4, DR7
VHNo 3HHV/CMV/EBVNo HHV/CMV/EBVNo HHV/CMV/EBV
TreatmentCS/AZA, LDLT and low-dose CS/FK506 after OPCS/AZA, UDCA RTX and low-dose CS for maintenanceCS/AZA, AZA for maintenance
OutcomeStabilized LFT and low SLEDAINormalized LFT and low SLEDAINormalized LFT and low SLEDAI